This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Whitaker, J. N Search for Related Content PubMed PubMed Citation Articles by Whitaker, J. N Social Bookmarking                   What's this?

Myelin basic protein in cerebrospinal fluid and other body fluids

Department of Neurology, University of Alabama at Birmingham and the Neurology and Research Services of the Birmingham Veterans Medical Center, Birmingham, Alabama, 35294-0007, USA

Myelin basic protein (MBP) or a fragment thereof may enter cerebrospinal fluid (CSF) and other body fluids in an etiologically nonspecific fashion to provide information about the status of central nervous system (CNS) myelin damage. MBP immunochemically detected is referred to as MBP-like material (MBPLM). The clinical utility of the assay for MBPLM in CSF is to document the presence, continuation, or resolution of CNS myelin injury. The analysis of CSF for MBPLM is subject to many variables, among which are the antisera and the form of the assay utilized. The dominant epitope of CSF MBPLM is in the decapeptide of 80-89 from the intact MBP molecule of 170 residues. Normally, CSF has no detected MBPLM. Following an acute relapse of MS, MBPLM rises quickly in the range of ng/ml and rapidly declines and disappears. The presence of MBPLM in CSF in chronic and progressive phases of the disease is unusual, but it may sometimes be detected in low levels, depending on the assay used for detection. The level of CSF MBPLM is related to both the mass of CNS myelin damage and how recently it occurred. The level of CSF MBPLM rarely is elevated in optic neuritis. The level of CSF MBPLM is unrelated to CSF protein level, level of IgG, presence of oligoclonal bands or pleocytosis. CSF MBPLM has the potential of serving as a marker of therapeutic effectiveness in MS and does have predictive value for response to glucocorticoids given for worsening of disease. The detection of MBPLM in body fluids other than CSF would be of great value because of the resulting improved feasibility for objectively monitoring the natural history of MS and response to therapy. Studies on blood have yet to produce a valid assay of MBPLM. Urinary MBPLM, though different in its features from that in CSF, may provide a correlate, not with acute demyelination in MS as is the case for CSF, but with progression of disease.

Key Words: cerebrospinal fluid • urine • myelin basic protein • multiple sclerosis • myelin

Multiple Sclerosis, Vol. 4, No. 1, 16-21 (1998)
DOI: 10.1177/135245859800400105


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				A. Jurewicz, M. Matysiak, C. S. Raine, and K. Selmaj Soluble Nogo-A, an inhibitor of axonal regeneration, as a biomarker for multiple sclerosis Neurology, January 23, 2007; 68(4): 283 - 287. [Abstract] [Full Text] [PDF]

				M. Ohta, K. Ohta, J. Ma, J. Takeuchi, T. Saida, M. Nishimura, and N. Itoh Clinical and Analytical Evaluation of an Enzyme Immunoassay for Myelin Basic Protein in Cerebrospinal Fluid Clin. Chem., September 1, 2000; 46(9): 1326 - 1330. [Abstract] [Full Text] [PDF]

				K. Bashir and J. N. Whitaker Clinical and laboratory features of primary progressive and secondary progressive MS Neurology, September 1, 1999; 53(4): 765 - 765. [Abstract] [Full Text] [PDF]

				J. N. Whitaker, B. A. Layton, A. A. Bartolucci, G. W. Mitchell, K. Bashir, J. Goodwin, and R. D. Kachelhofer Urinary Myelin Basic Protein-like Material in Patients With Multiple Sclerosis During Interferon Beta-1b Treatment Arch Neurol, June 1, 1999; 56(6): 687 - 691. [Abstract] [Full Text] [PDF]